Pipeline Report

Updated February 1st, 2026

BuyandBill.com Analytics Pro Features

Unlock Full Access to
BuyandBill.com Analytics

Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.

You attempted to open: Drug Pipeline Report
10+ Years of Historical Pricing Data
Unlimited Access to All Drug Pages
Comparative & Historical Drug Pricing Reports
PriceDoctoRx Self-Administered Drug Pricing
Medicare & Medicaid Claims Data
Drug Pipeline Report
Check Out New Features
Comparative Pricing Reports

Search

Descriptive Alt Text

Filters

Showing results 129–136 of 4,419
Manufacturer ▼ Drug Name Indication Stage Status Route of Administration Drug Class
Adagene Inc. muzastotug (ADG126) combined with KEYTRUDA (pembrolizumab) - (ADG126-P001/KEYNOTE-C98) Solid tumors Phase 2 Ongoing Intravenous infusion Oncology
Adagene Inc. ADG106-P2001 Solid tumors Phase 2 Ongoing Intravenous Oncology
Adaptimmune Therapeutics plc ADP-A2M4CD8 - (SURPASS-3) Ovarian Cancer Phase 2 Clinical Pause Intravenous Oncology
Adaptimmune Therapeutics plc ADP-A2M4CD8 - (SURPASS-2) Esophageal and esophagogastric junction cancers Phase 2 Trial Completed Intravenous Oncology
Adaptimmune Therapeutics plc Afami-cel - (SPEARHEAD-2) Head & neck cancer Phase 2/3 Trial Completed Intravenous Oncology
Adaptimmune Therapeutics plc ADP-A2M4CD8 - (SURPASS-2) Esophageal and esophagogastric junction cancers Phase 2 Trial Completed Intravenous Oncology
Adaptimmune Therapeutics plc Lete-cel - (IGNYTE-ESO) Sarcoma BLA Filing Data Released Intravenous Oncology
Adaptimmune Therapeutics plc ADP-A2M4CD8 - (SURPASS-3) Ovarian Cancer Phase 2 Clinical Pause Intravenous Oncology